25 February 2022 - EMA has recommended granting a marketing authorisation in the European Union (EU) for Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.

Tebentafusp, the active substance of Kimmtrak, is a type of treatment called a bispecific fusion protein. It works by helping immune cells to get close enough to the cancer cells to attack them. The treatment can be used in adult patients who are human leukocyte antigen (HLA)-A*02:01-positive and have unresectable (cannot be removed surgically) or metastatic uveal melanoma.

Read EMA press release